NEO6860, a TRPV1 Antagonist, First in Human Study

NCT02337543 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Osteoarthritis, Knee

Interventions

DRUG: NEO6860
DRUG: Placebo

Sponsor

Neomed Institute

Collaborators

[object Object]